.png){kind=icon}
.png){kind=icon}
Return
Developing antisense therapeutics for multiple myeloma
.png){kind=icon}
OA
AI
DOI：10.1016/j.xcrp.2025.102923.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
MicroRNAs (miRNAs) are concise non-coding RNA molecules crucial for post-transcriptional gene expression regulation through their binding and inhibition of the messenger RNAs (mRNAs) of specific genes. In cancer, irregular miRNA expression disrupts the equilibrium of oncogenes or tumor-suppressor genes, potentially increasing tumor initiation, progression, and metastasis. Antisense and anti-miRNA-based therapies target the gene-regulative mechanisms of multiple myeloma (MM) progression, potentially offering a promising avenue for MM treatment. MM is a hematological malignancy characterized by uncontrolled proliferation and dissemination of plasma cells (PCs) in the bone marrow, accompanied by immunodeficiency, renal insufficiency, lytic bone loss, and an excess of a single immunoglobulin. Despite numerous investigations into the roles of miRNAs and gene targets in tumor and bone disorder progression, limited attention has been directed toward antisense oligonucleotide (ASO)-based methodologies. This review aims to present a comprehensive overview of the role of miRNAs and gene targets in MM and summarizes current ASOs with a focus on identifying high-yield targets to enhance MM regimens.
Keywords:
multiple myeloma
gene therapy
antisense oligonucleotides
microRNA
peptide nucleic acid
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
7.3
Papers:
2.7K
Citations:
1.2W